Democritus University of Thrace (DUTH)
Διερεύνηση του ρόλου της γενετικής ποικιλομορφίας των Core/Core+1 πρωτεϊνών του ιού της ηπατίτιδας C στη βιολογική δράση των ιικών πρωτεϊνών και στην παθογένεια της λοίμωξης από τον ιό
Abstract
dc:descriptionHepatitis C virus (HCV) infection is a major cause of chronic liver disease that often leads to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCV affects approximately 115 million people worldwide. HCV belongs to the genus hepacivirus of the Flaviviridae family. The single-stranded positive-sense RNA genome of HCV (9.6 kb) encodes a polyprotein precursor which is cleaved by cellular and viral proteases to yield 10 structural and non-structural mature proteins. Translation of the polyprotein is mediated by an internal ribosome entry site (IRES) embedded within the 5’ UTR. HCV genome contains a second functional open reading frame (ORF) within the core region, encoding a protein known as ARFP (alternative reading frame protein), F or core+1. Two predominant isoforms of core+1/ARFP have been reported, designated as core+1/S (short) and core+1/L (long), which are produced by Internal translation initiation. The biological role of core+1/ARF protein remains elusive. However, several independent studies have shown the presence of specific anti-core+1/ARFP antibodies in chronically HCV-infected patients, supporting the suggestion that core+1/ARFP is expressed during natural HCV infection. The aim of this PhD thesis is to understand the biological function of core+1/ARF protein in virus associated pathogenesis and also to investigate the molecular mechanisms regulating core+1/ARFP expression. Firstly, we determined, for the first time, the prevalence of anti-core+1 antibodies in HCV patients with cirrhosis. Using an in-house ELISA, we assessed the levels of anti-core+1 antibodies in chronically HCV-infected patients at different stages of cirrhosis in comparison to chronic HCV patients without cirrhosis. 28.7% of HCV patients with cirrhosis were positive for anti-core+1/ARFP antibodies, in contrast with 16.5% of non-cirrhotic HCV patients (p=0.0026). Moreover, there was a significantly higher positivity for anti-core+1 antibodies in HCV patients with advanced cirrhosis (MELD≥15) (36.7 %) compared to those with early cirrhosis (MELD<15) (24 %) (p<0.05). In addition, the levels of alanine transaminase (ALT) were significantly reduced in cirrhotic patients who were positive for anti-core+1 antibodies (p=0.0145). These findings, together with previously published study, supporting the high prevalence of anti-core+1/ARFP antibodies in HCV patients with HCC, suggest that core+1/ARF protein may play a role in virus-associated pathogenesis, and provide evidence to suggest that the levels of anti-core+1 antibodies may serve as a marker for disease progression.In addition, we studied core+1/ARF protein’s expression through two different experimental systems. (a) Firstly, we used HCV JFH1-based bicistronic replicons in order to determine, to a greater extent, the molecular mechanisms regulating core+1/L(Long) expression. JFH1 replicons containing the firefly luciferase (luc) gene, cloned in frame with core+1 sequence, were used. A number of mutations were designed in JFH1 replicons, which were expected to abolish the production of core protein, in order to investigate a possible correlation between the expression of the overlapping core and core+1 ORFs. The mutated JFH1 replicons were introduced into the human hepatoma Huh7-Lunet cells and core+1/ARFP expression was measured. Our results suggest that, possibly, core+1/ARFP expression is mediated by a non-canonical translational mechanism, such as ribosomal shunting. (b) Moreover, a polyclonal antibody against a recombinant core+1/ARF protein of the infectious HCV/JFH1 strain was produced in order to investigate the expression of core+1/ARF protein in cells infected with JFH1 full-length replicons, in the in vitro HCV infectious system. However, the detection of core+1/ARF protein in this system was not possible. Finally, the investigation for the presence of mutations in the core/core+1 region of specific HCV genotype 2 isolates, resulted in the identification of recombinant HCV strains in Greece, for the first time. The detection of the recombinant strains came after the observation that an unusually high rate of HCV type 2 infected patients could not establish sustained virological response after Peg-IFNα/RBV treatment. The sequence of the viral genome of the HCV-type 2 isolates, was analyzed through PCR-sequencing, in order to detect mutations in the core/core+1 region, associated with IFN therapy resistance. Sequence analysis of core-Ε1 region revealed that three patients were infected with HCV strains, phylogenetically related to the intergenotypic 2k/1b recombinant strain, firstly reported in Russia (RF1_ 2k/1b). Further analysis of viral and host genome aimed at the investigation of the IFN-resistance attributes. The identification of recombinant strains is very important for the selection of the appropriate treatment protocol, if IFN/RBV treatment is concerned.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kassela, Aikaterini
- Κασσελά, Αικατερίνη
Subjects
dc:subject × 20- Ανασυνδυασμός
- Βιοδείκτης
- Εναλλακτικοί μηχανισμοί μετάφρασης
- Ιός της ηπατίτιδας C
- Πρωτεΐνη εναλλακτικού πλαισίου ανάγνωσης
- Κίρρωση του ήπατος
- Recombination
- Biomarker
- Non-canonical translation
- Hepatitis C virus (HCV)
- Alternative reading frame protein
- Liver cirrhosis
- Φυσικές Επιστήμες
- Βιολογία
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Natural Sciences
- Biological Sciences
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42549